Study of E7046 in Subjects With Selected Advanced Malignancies
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02540291
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT02513472
- Locations
- ๐บ๐ธ
Facility #2, San Antonio, Texas, United States
๐บ๐ธFacility #1, Madison, Wisconsin, United States
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 357
- Registration Number
- NCT02501096
- Locations
- ๐บ๐ธ
The University of Chicago, Chicago, Illinois, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธMass General Hospital, Boston, Massachusetts, United States
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT02481050
- Locations
- ๐บ๐ธ
Facility #1, Winchester, Virginia, United States
๐บ๐ธFacility #2, Dallas, Texas, United States
A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02421042
Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT02415790
- Locations
- ๐บ๐ธ
Paraxel International, Glendale, California, United States
A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02398669
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials, Anaheim, California, United States
Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder
Phase 1
Completed
- Conditions
- Insomnia Disorder
- Interventions
- Drug: Lemborexant-matched placebo.
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT02350309
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
Phase 2
Terminated
- Conditions
- Alzheimer DiseaseDementia, Alzheimer Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02322021
An Extended Access Program (EAP) for Perampanel
- Conditions
- Primary Generalized Tonic-Clonic or Partial Onset SeizuresLennox Gastaut Syndrome
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT02307578
- Locations
- ๐ช๐ช
Tartu University Hospital, Tartu, Estonia
๐ง๐ชHรดpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium
๐ง๐ชCentre Neurologique William Lennox, Ottignies, Belgium
ยฉ Copyright 2025. All Rights Reserved by MedPath